BMS exits Cellares partnership, triggering layoffs and restructuring
Bristol Myers Squibb has terminated its partnership with cell therapy manufacturer Cellares, prompting the latter to lay off 100 employees. The decision follows a comprehensive evaluation by BMS and forces Cellares to restructure despite recent funding and other client commitments.
Key points
- Bristol Myers Squibb ended its collaboration with Cellares after a 'comprehensive evaluation,' according to Endpoints News.
- Cellares plans to lay off 100 staff by October 20, primarily software engineers, quality control, and manufacturing specialists, per a California WARN Act filing.
- The terminated deal involved potential payouts totaling $380 million, as noted by Fierce Pharma.
- Cellares recently closed a $327 million Series D round and has doubled its customer base since the start of 2026, according to BioPharma Dive.
- CEO Fabian Gerlinghaus stated the company's technology remains clinically proven and other partners have reaffirmed their commitments.
Background
This development occurs amid broader pharma consolidation, including reported merger talks between Bristol Myers Squibb and AstraZeneca. Cellares had previously secured FDA recognition through its PreCheck Pilot Program and established partnerships with Gilead’s Kite Pharma and Sonoma Biotherapeutics.
How outlets are covering it
Endpoints News focuses on the termination following a 'comprehensive evaluation' by Bristol Myers Squibb. BioPharma Dive emphasizes the financial impact, highlighting the layoffs and the recent $327 million funding round. Fierce Pharma notes that Cellares describes the exit as specific to one customer and stresses that the company's technology is validated in clinical settings, with other partners continuing to engage.
Why it matters
The loss of a major pharmaceutical partner like Bristol Myers Squibb tests the resilience of Cellares' business model. While the company faces immediate workforce reductions, its continued partnerships and recent funding suggest it may sustain operations, though the incident highlights risks in relying on large-scale manufacturing contracts.
What to watch
Cellares will complete the layoffs by October 20. The company intends to concentrate resources on existing clinical and commercial programs, while other partners may accelerate collaborations or discuss new initiatives.
- Bristol Myers ends deal with Cellares, cell therapy manufacturer to reorg Endpoints News
- Bristol Myers ends blood cancer drug deal with cell therapy maker Cellares Reuters
- Cellares, a cell therapy manufacturing specialist, to lay off 100 employees BioPharma Dive
- Cellares CEO seeks to 'resize' company after loss of 'large' cell therapy manufacturing customer Fierce Pharma
- Fast-growing biotech startup Cellares plans layoffs after losing major customer The Business Journals
Want the full story? Read the original reporting
Read on Endpoints News